nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Miliaria—Ursodeoxycholic acid—primary biliary cirrhosis	0.0202	0.027	CcSEcCtD
Naltrexone—Miliaria—Chenodeoxycholic acid—primary biliary cirrhosis	0.0202	0.027	CcSEcCtD
Naltrexone—ABCB1—Drug Induction of Bile Acid Pathway—SLC51B—primary biliary cirrhosis	0.0171	0.0693	CbGpPWpGaD
Naltrexone—UGT1A1—Codeine and Morphine Metabolism—ABCC2—primary biliary cirrhosis	0.0156	0.0632	CbGpPWpGaD
Naltrexone—Ileus paralytic—Colchicine—primary biliary cirrhosis	0.0153	0.0204	CcSEcCtD
Naltrexone—Appetite absent—Colchicine—primary biliary cirrhosis	0.0133	0.0177	CcSEcCtD
Naltrexone—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—primary biliary cirrhosis	0.013	0.0525	CbGpPWpGaD
Naltrexone—UGT1A1—Irinotecan Pathway—ABCC2—primary biliary cirrhosis	0.00998	0.0404	CbGpPWpGaD
Naltrexone—Abdominal cramps—Colchicine—primary biliary cirrhosis	0.0098	0.0131	CcSEcCtD
Naltrexone—Pharyngolaryngeal pain—Colchicine—primary biliary cirrhosis	0.0098	0.0131	CcSEcCtD
Naltrexone—Laryngeal pain—Colchicine—primary biliary cirrhosis	0.0097	0.013	CcSEcCtD
Naltrexone—ABCB1—Abacavir transmembrane transport—ABCG2—primary biliary cirrhosis	0.00887	0.0359	CbGpPWpGaD
Naltrexone—Abdominal cramps—Ursodeoxycholic acid—primary biliary cirrhosis	0.0088	0.0118	CcSEcCtD
Naltrexone—Abdominal cramps—Chenodeoxycholic acid—primary biliary cirrhosis	0.0088	0.0118	CcSEcCtD
Naltrexone—UGT1A1—Irinotecan Pathway—ABCG2—primary biliary cirrhosis	0.00849	0.0343	CbGpPWpGaD
Naltrexone—Gamma-glutamyltransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00722	0.00964	CcSEcCtD
Naltrexone—Gamma-glutamyltransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00722	0.00964	CcSEcCtD
Naltrexone—ABCB1—Codeine and Morphine Metabolism—ABCC2—primary biliary cirrhosis	0.00717	0.029	CbGpPWpGaD
Naltrexone—Cellulitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00653	0.00872	CcSEcCtD
Naltrexone—Cellulitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00653	0.00872	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00628	0.00839	CcSEcCtD
Naltrexone—Hepatic enzyme increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00628	0.00839	CcSEcCtD
Naltrexone—UGT1A1—Constitutive Androstane Receptor Pathway—ABCC2—primary biliary cirrhosis	0.00515	0.0208	CbGpPWpGaD
Naltrexone—ABCB1—Abacavir transport and metabolism—ABCG2—primary biliary cirrhosis	0.0051	0.0206	CbGpPWpGaD
Naltrexone—Lymphadenopathy—Chenodeoxycholic acid—primary biliary cirrhosis	0.00506	0.00675	CcSEcCtD
Naltrexone—Lymphadenopathy—Ursodeoxycholic acid—primary biliary cirrhosis	0.00506	0.00675	CcSEcCtD
Naltrexone—Sleep disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00498	0.00665	CcSEcCtD
Naltrexone—Sleep disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00498	0.00665	CcSEcCtD
Naltrexone—Purpura—Colchicine—primary biliary cirrhosis	0.00498	0.00665	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Colchicine—primary biliary cirrhosis	0.0048	0.00641	CcSEcCtD
Naltrexone—Cardiac failure congestive—Chenodeoxycholic acid—primary biliary cirrhosis	0.00476	0.00635	CcSEcCtD
Naltrexone—Cardiac failure congestive—Ursodeoxycholic acid—primary biliary cirrhosis	0.00476	0.00635	CcSEcCtD
Naltrexone—Atrial fibrillation—Chenodeoxycholic acid—primary biliary cirrhosis	0.00455	0.00608	CcSEcCtD
Naltrexone—Atrial fibrillation—Ursodeoxycholic acid—primary biliary cirrhosis	0.00455	0.00608	CcSEcCtD
Naltrexone—Dehydration—Colchicine—primary biliary cirrhosis	0.00446	0.00596	CcSEcCtD
Naltrexone—Arthritis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00444	0.00592	CcSEcCtD
Naltrexone—Arthritis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00444	0.00592	CcSEcCtD
Naltrexone—OPRD1—Peptide GPCRs—CXCR5—primary biliary cirrhosis	0.00442	0.0179	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—primary biliary cirrhosis	0.00432	0.0175	CbGpPWpGaD
Naltrexone—Aspartate aminotransferase increased—Colchicine—primary biliary cirrhosis	0.00432	0.00577	CcSEcCtD
Naltrexone—Cramp muscle—Colchicine—primary biliary cirrhosis	0.00432	0.00577	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Ursodeoxycholic acid—primary biliary cirrhosis	0.00431	0.00576	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Chenodeoxycholic acid—primary biliary cirrhosis	0.00431	0.00576	CcSEcCtD
Naltrexone—Migraine—Chenodeoxycholic acid—primary biliary cirrhosis	0.00425	0.00567	CcSEcCtD
Naltrexone—Migraine—Ursodeoxycholic acid—primary biliary cirrhosis	0.00425	0.00567	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Colchicine—primary biliary cirrhosis	0.00423	0.00565	CcSEcCtD
Naltrexone—Face oedema—Chenodeoxycholic acid—primary biliary cirrhosis	0.00416	0.00556	CcSEcCtD
Naltrexone—Face oedema—Ursodeoxycholic acid—primary biliary cirrhosis	0.00416	0.00556	CcSEcCtD
Naltrexone—Dehydration—Chenodeoxycholic acid—primary biliary cirrhosis	0.00401	0.00536	CcSEcCtD
Naltrexone—Dehydration—Ursodeoxycholic acid—primary biliary cirrhosis	0.00401	0.00536	CcSEcCtD
Naltrexone—Abdominal discomfort—Colchicine—primary biliary cirrhosis	0.00398	0.00531	CcSEcCtD
Naltrexone—Abdominal pain upper—Chenodeoxycholic acid—primary biliary cirrhosis	0.00394	0.00526	CcSEcCtD
Naltrexone—Abdominal pain upper—Ursodeoxycholic acid—primary biliary cirrhosis	0.00394	0.00526	CcSEcCtD
Naltrexone—ABCB1—Drug Induction of Bile Acid Pathway—ABCC2—primary biliary cirrhosis	0.00392	0.0159	CbGpPWpGaD
Naltrexone—Aspartate aminotransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00388	0.00519	CcSEcCtD
Naltrexone—Cramp muscle—Chenodeoxycholic acid—primary biliary cirrhosis	0.00388	0.00519	CcSEcCtD
Naltrexone—Cramp muscle—Ursodeoxycholic acid—primary biliary cirrhosis	0.00388	0.00519	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00388	0.00519	CcSEcCtD
Naltrexone—OPRK1—Peptide GPCRs—CXCR5—primary biliary cirrhosis	0.00387	0.0157	CbGpPWpGaD
Naltrexone—Alanine aminotransferase increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.0038	0.00508	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.0038	0.00508	CcSEcCtD
Naltrexone—Influenza—Chenodeoxycholic acid—primary biliary cirrhosis	0.00373	0.00498	CcSEcCtD
Naltrexone—Influenza—Ursodeoxycholic acid—primary biliary cirrhosis	0.00373	0.00498	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IGFBP1—primary biliary cirrhosis	0.00368	0.0149	CbGpPWpGaD
Naltrexone—Angina pectoris—Ursodeoxycholic acid—primary biliary cirrhosis	0.00363	0.00485	CcSEcCtD
Naltrexone—Angina pectoris—Chenodeoxycholic acid—primary biliary cirrhosis	0.00363	0.00485	CcSEcCtD
Naltrexone—Bronchitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00359	0.00479	CcSEcCtD
Naltrexone—Bronchitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00359	0.00479	CcSEcCtD
Naltrexone—Abdominal discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.00357	0.00477	CcSEcCtD
Naltrexone—Abdominal discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.00357	0.00477	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.00346	0.00463	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.00346	0.00463	CcSEcCtD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB4—primary biliary cirrhosis	0.00343	0.0139	CbGpPWpGaD
Naltrexone—Weight increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00339	0.00453	CcSEcCtD
Naltrexone—Weight increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00339	0.00453	CcSEcCtD
Naltrexone—Weight decreased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00337	0.0045	CcSEcCtD
Naltrexone—Weight decreased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00337	0.0045	CcSEcCtD
Naltrexone—Pneumonia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00334	0.00446	CcSEcCtD
Naltrexone—Pneumonia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00334	0.00446	CcSEcCtD
Naltrexone—Infestation—Ursodeoxycholic acid—primary biliary cirrhosis	0.00332	0.00444	CcSEcCtD
Naltrexone—Infestation NOS—Ursodeoxycholic acid—primary biliary cirrhosis	0.00332	0.00444	CcSEcCtD
Naltrexone—Infestation—Chenodeoxycholic acid—primary biliary cirrhosis	0.00332	0.00444	CcSEcCtD
Naltrexone—Infestation NOS—Chenodeoxycholic acid—primary biliary cirrhosis	0.00332	0.00444	CcSEcCtD
Naltrexone—Depression—Chenodeoxycholic acid—primary biliary cirrhosis	0.00331	0.00442	CcSEcCtD
Naltrexone—Depression—Ursodeoxycholic acid—primary biliary cirrhosis	0.00331	0.00442	CcSEcCtD
Naltrexone—Acute coronary syndrome—Chenodeoxycholic acid—primary biliary cirrhosis	0.00328	0.00437	CcSEcCtD
Naltrexone—Acute coronary syndrome—Ursodeoxycholic acid—primary biliary cirrhosis	0.00328	0.00437	CcSEcCtD
Naltrexone—OPRM1—Peptide GPCRs—CXCR5—primary biliary cirrhosis	0.00327	0.0132	CbGpPWpGaD
Naltrexone—Myocardial infarction—Chenodeoxycholic acid—primary biliary cirrhosis	0.00326	0.00435	CcSEcCtD
Naltrexone—Myocardial infarction—Ursodeoxycholic acid—primary biliary cirrhosis	0.00326	0.00435	CcSEcCtD
Naltrexone—Conjunctivitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00323	0.00431	CcSEcCtD
Naltrexone—Conjunctivitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00323	0.00431	CcSEcCtD
Naltrexone—Urinary tract infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.00323	0.00431	CcSEcCtD
Naltrexone—Urinary tract infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.00323	0.00431	CcSEcCtD
Naltrexone—Hepatobiliary disease—Chenodeoxycholic acid—primary biliary cirrhosis	0.00314	0.0042	CcSEcCtD
Naltrexone—Hepatobiliary disease—Ursodeoxycholic acid—primary biliary cirrhosis	0.00314	0.0042	CcSEcCtD
Naltrexone—Epistaxis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00314	0.00419	CcSEcCtD
Naltrexone—Epistaxis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00314	0.00419	CcSEcCtD
Naltrexone—Sinusitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00312	0.00416	CcSEcCtD
Naltrexone—Sinusitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00312	0.00416	CcSEcCtD
Naltrexone—Eye disorder—Colchicine—primary biliary cirrhosis	0.0031	0.00414	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—CD3D—primary biliary cirrhosis	0.0031	0.0125	CbGpPWpGaD
Naltrexone—Mediastinal disorder—Colchicine—primary biliary cirrhosis	0.00299	0.004	CcSEcCtD
Naltrexone—Pharyngitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00296	0.00395	CcSEcCtD
Naltrexone—Pharyngitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00296	0.00395	CcSEcCtD
Naltrexone—Alopecia—Colchicine—primary biliary cirrhosis	0.00293	0.00392	CcSEcCtD
Naltrexone—Connective tissue disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00293	0.00391	CcSEcCtD
Naltrexone—Connective tissue disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00293	0.00391	CcSEcCtD
Naltrexone—Malnutrition—Colchicine—primary biliary cirrhosis	0.00289	0.00386	CcSEcCtD
Naltrexone—UGT1A1—Constitutive Androstane Receptor Pathway—PPARGC1A—primary biliary cirrhosis	0.00286	0.0116	CbGpPWpGaD
Naltrexone—Eye disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00279	0.00372	CcSEcCtD
Naltrexone—Eye disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00279	0.00372	CcSEcCtD
Naltrexone—Tinnitus—Chenodeoxycholic acid—primary biliary cirrhosis	0.00278	0.00371	CcSEcCtD
Naltrexone—Tinnitus—Ursodeoxycholic acid—primary biliary cirrhosis	0.00278	0.00371	CcSEcCtD
Naltrexone—Muscle spasms—Colchicine—primary biliary cirrhosis	0.00278	0.00371	CcSEcCtD
Naltrexone—Cardiac disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00277	0.0037	CcSEcCtD
Naltrexone—Cardiac disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00277	0.0037	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—primary biliary cirrhosis	0.00272	0.011	CbGpPWpGaD
Naltrexone—Angiopathy—Ursodeoxycholic acid—primary biliary cirrhosis	0.00271	0.00361	CcSEcCtD
Naltrexone—Angiopathy—Chenodeoxycholic acid—primary biliary cirrhosis	0.00271	0.00361	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—MAP3K14—primary biliary cirrhosis	0.0027	0.0109	CbGpPWpGaD
Naltrexone—Immune system disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.0027	0.0036	CcSEcCtD
Naltrexone—Immune system disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.0027	0.0036	CcSEcCtD
Naltrexone—Mediastinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00269	0.00359	CcSEcCtD
Naltrexone—Mediastinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00269	0.00359	CcSEcCtD
Naltrexone—Chills—Chenodeoxycholic acid—primary biliary cirrhosis	0.00268	0.00357	CcSEcCtD
Naltrexone—Chills—Ursodeoxycholic acid—primary biliary cirrhosis	0.00268	0.00357	CcSEcCtD
Naltrexone—Angioedema—Colchicine—primary biliary cirrhosis	0.00264	0.00353	CcSEcCtD
Naltrexone—Alopecia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00264	0.00352	CcSEcCtD
Naltrexone—Alopecia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00264	0.00352	CcSEcCtD
Naltrexone—Malnutrition—Chenodeoxycholic acid—primary biliary cirrhosis	0.0026	0.00347	CcSEcCtD
Naltrexone—Malnutrition—Ursodeoxycholic acid—primary biliary cirrhosis	0.0026	0.00347	CcSEcCtD
Naltrexone—Flatulence—Ursodeoxycholic acid—primary biliary cirrhosis	0.00256	0.00342	CcSEcCtD
Naltrexone—Flatulence—Chenodeoxycholic acid—primary biliary cirrhosis	0.00256	0.00342	CcSEcCtD
Naltrexone—Tension—Chenodeoxycholic acid—primary biliary cirrhosis	0.00255	0.0034	CcSEcCtD
Naltrexone—Tension—Ursodeoxycholic acid—primary biliary cirrhosis	0.00255	0.0034	CcSEcCtD
Naltrexone—Nervousness—Chenodeoxycholic acid—primary biliary cirrhosis	0.00252	0.00337	CcSEcCtD
Naltrexone—Nervousness—Ursodeoxycholic acid—primary biliary cirrhosis	0.00252	0.00337	CcSEcCtD
Naltrexone—Buprenorphine—ABCG2—primary biliary cirrhosis	0.00252	0.698	CrCbGaD
Naltrexone—Back pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00251	0.00335	CcSEcCtD
Naltrexone—Back pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00251	0.00335	CcSEcCtD
Naltrexone—Muscle spasms—Chenodeoxycholic acid—primary biliary cirrhosis	0.0025	0.00333	CcSEcCtD
Naltrexone—Muscle spasms—Ursodeoxycholic acid—primary biliary cirrhosis	0.0025	0.00333	CcSEcCtD
Naltrexone—Myalgia—Colchicine—primary biliary cirrhosis	0.00246	0.00329	CcSEcCtD
Naltrexone—Arthralgia—Colchicine—primary biliary cirrhosis	0.00246	0.00329	CcSEcCtD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—MAS1—primary biliary cirrhosis	0.00244	0.00985	CbGpPWpGaD
Naltrexone—Ill-defined disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00241	0.00322	CcSEcCtD
Naltrexone—Ill-defined disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00241	0.00322	CcSEcCtD
Naltrexone—Angioedema—Chenodeoxycholic acid—primary biliary cirrhosis	0.00237	0.00317	CcSEcCtD
Naltrexone—Angioedema—Ursodeoxycholic acid—primary biliary cirrhosis	0.00237	0.00317	CcSEcCtD
Naltrexone—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—primary biliary cirrhosis	0.00236	0.00956	CbGpPWpGaD
Naltrexone—Malaise—Chenodeoxycholic acid—primary biliary cirrhosis	0.00234	0.00313	CcSEcCtD
Naltrexone—Malaise—Ursodeoxycholic acid—primary biliary cirrhosis	0.00234	0.00313	CcSEcCtD
Naltrexone—Syncope—Chenodeoxycholic acid—primary biliary cirrhosis	0.00233	0.00311	CcSEcCtD
Naltrexone—Syncope—Ursodeoxycholic acid—primary biliary cirrhosis	0.00233	0.00311	CcSEcCtD
Naltrexone—Shock—Colchicine—primary biliary cirrhosis	0.00232	0.0031	CcSEcCtD
Naltrexone—Nervous system disorder—Colchicine—primary biliary cirrhosis	0.00231	0.00309	CcSEcCtD
Naltrexone—Palpitations—Chenodeoxycholic acid—primary biliary cirrhosis	0.0023	0.00306	CcSEcCtD
Naltrexone—Palpitations—Ursodeoxycholic acid—primary biliary cirrhosis	0.0023	0.00306	CcSEcCtD
Naltrexone—Skin disorder—Colchicine—primary biliary cirrhosis	0.00229	0.00306	CcSEcCtD
Naltrexone—Loss of consciousness—Chenodeoxycholic acid—primary biliary cirrhosis	0.00228	0.00305	CcSEcCtD
Naltrexone—Loss of consciousness—Ursodeoxycholic acid—primary biliary cirrhosis	0.00228	0.00305	CcSEcCtD
Naltrexone—Cough—Chenodeoxycholic acid—primary biliary cirrhosis	0.00227	0.00303	CcSEcCtD
Naltrexone—Cough—Ursodeoxycholic acid—primary biliary cirrhosis	0.00227	0.00303	CcSEcCtD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—primary biliary cirrhosis	0.00225	0.00911	CbGpPWpGaD
Naltrexone—Convulsion—Chenodeoxycholic acid—primary biliary cirrhosis	0.00225	0.003	CcSEcCtD
Naltrexone—Convulsion—Ursodeoxycholic acid—primary biliary cirrhosis	0.00225	0.003	CcSEcCtD
Naltrexone—Hypertension—Ursodeoxycholic acid—primary biliary cirrhosis	0.00224	0.00299	CcSEcCtD
Naltrexone—Hypertension—Chenodeoxycholic acid—primary biliary cirrhosis	0.00224	0.00299	CcSEcCtD
Naltrexone—Chest pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Myalgia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Arthralgia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Chest pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Arthralgia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Myalgia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00221	0.00295	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Chenodeoxycholic acid—primary biliary cirrhosis	0.0022	0.00293	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Ursodeoxycholic acid—primary biliary cirrhosis	0.0022	0.00293	CcSEcCtD
Naltrexone—OPRM1—IL4-mediated signaling events—COL1A1—primary biliary cirrhosis	0.0022	0.00888	CbGpPWpGaD
Naltrexone—Discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.00219	0.00292	CcSEcCtD
Naltrexone—Discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.00219	0.00292	CcSEcCtD
Naltrexone—Dry mouth—Ursodeoxycholic acid—primary biliary cirrhosis	0.00216	0.00289	CcSEcCtD
Naltrexone—Dry mouth—Chenodeoxycholic acid—primary biliary cirrhosis	0.00216	0.00289	CcSEcCtD
Naltrexone—ABCB1—ABC-family proteins mediated transport—ABCC2—primary biliary cirrhosis	0.00215	0.0087	CbGpPWpGaD
Naltrexone—Musculoskeletal discomfort—Colchicine—primary biliary cirrhosis	0.00215	0.00287	CcSEcCtD
Naltrexone—Confusional state—Ursodeoxycholic acid—primary biliary cirrhosis	0.00214	0.00285	CcSEcCtD
Naltrexone—Confusional state—Chenodeoxycholic acid—primary biliary cirrhosis	0.00214	0.00285	CcSEcCtD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—MAS1—primary biliary cirrhosis	0.00214	0.00864	CbGpPWpGaD
Naltrexone—Oedema—Chenodeoxycholic acid—primary biliary cirrhosis	0.00212	0.00283	CcSEcCtD
Naltrexone—Oedema—Ursodeoxycholic acid—primary biliary cirrhosis	0.00212	0.00283	CcSEcCtD
Naltrexone—Infection—Chenodeoxycholic acid—primary biliary cirrhosis	0.00211	0.00281	CcSEcCtD
Naltrexone—Infection—Ursodeoxycholic acid—primary biliary cirrhosis	0.00211	0.00281	CcSEcCtD
Naltrexone—Shock—Ursodeoxycholic acid—primary biliary cirrhosis	0.00209	0.00278	CcSEcCtD
Naltrexone—Shock—Chenodeoxycholic acid—primary biliary cirrhosis	0.00209	0.00278	CcSEcCtD
Naltrexone—Nervous system disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00208	0.00278	CcSEcCtD
Naltrexone—Nervous system disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00208	0.00278	CcSEcCtD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCR5—primary biliary cirrhosis	0.00208	0.0084	CbGpPWpGaD
Naltrexone—Tachycardia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00207	0.00276	CcSEcCtD
Naltrexone—Tachycardia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00207	0.00276	CcSEcCtD
Naltrexone—Skin disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00206	0.00275	CcSEcCtD
Naltrexone—Skin disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00206	0.00275	CcSEcCtD
Naltrexone—Decreased appetite—Colchicine—primary biliary cirrhosis	0.00205	0.00274	CcSEcCtD
Naltrexone—Hyperhidrosis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00205	0.00274	CcSEcCtD
Naltrexone—Hyperhidrosis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00205	0.00274	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Colchicine—primary biliary cirrhosis	0.00204	0.00272	CcSEcCtD
Naltrexone—Fatigue—Colchicine—primary biliary cirrhosis	0.00203	0.00272	CcSEcCtD
Naltrexone—Anorexia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00202	0.0027	CcSEcCtD
Naltrexone—Anorexia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00202	0.0027	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Chenodeoxycholic acid—primary biliary cirrhosis	0.00193	0.00258	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Ursodeoxycholic acid—primary biliary cirrhosis	0.00193	0.00258	CcSEcCtD
Naltrexone—Gastrointestinal pain—Colchicine—primary biliary cirrhosis	0.00193	0.00258	CcSEcCtD
Naltrexone—Insomnia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00192	0.00256	CcSEcCtD
Naltrexone—Insomnia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00192	0.00256	CcSEcCtD
Naltrexone—Paraesthesia—Ursodeoxycholic acid—primary biliary cirrhosis	0.0019	0.00254	CcSEcCtD
Naltrexone—Paraesthesia—Chenodeoxycholic acid—primary biliary cirrhosis	0.0019	0.00254	CcSEcCtD
Naltrexone—Dyspnoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.00189	0.00252	CcSEcCtD
Naltrexone—Dyspnoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.00189	0.00252	CcSEcCtD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL9—primary biliary cirrhosis	0.00189	0.00763	CbGpPWpGaD
Naltrexone—Somnolence—Chenodeoxycholic acid—primary biliary cirrhosis	0.00188	0.00252	CcSEcCtD
Naltrexone—Somnolence—Ursodeoxycholic acid—primary biliary cirrhosis	0.00188	0.00252	CcSEcCtD
Naltrexone—Urticaria—Colchicine—primary biliary cirrhosis	0.00187	0.0025	CcSEcCtD
Naltrexone—Abdominal pain—Colchicine—primary biliary cirrhosis	0.00187	0.00249	CcSEcCtD
Naltrexone—Decreased appetite—Ursodeoxycholic acid—primary biliary cirrhosis	0.00184	0.00246	CcSEcCtD
Naltrexone—Decreased appetite—Chenodeoxycholic acid—primary biliary cirrhosis	0.00184	0.00246	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Ursodeoxycholic acid—primary biliary cirrhosis	0.00183	0.00244	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Chenodeoxycholic acid—primary biliary cirrhosis	0.00183	0.00244	CcSEcCtD
Naltrexone—Fatigue—Ursodeoxycholic acid—primary biliary cirrhosis	0.00183	0.00244	CcSEcCtD
Naltrexone—Fatigue—Chenodeoxycholic acid—primary biliary cirrhosis	0.00183	0.00244	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCR5—primary biliary cirrhosis	0.00182	0.00736	CbGpPWpGaD
Naltrexone—Pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00181	0.00242	CcSEcCtD
Naltrexone—Constipation—Chenodeoxycholic acid—primary biliary cirrhosis	0.00181	0.00242	CcSEcCtD
Naltrexone—Constipation—Ursodeoxycholic acid—primary biliary cirrhosis	0.00181	0.00242	CcSEcCtD
Naltrexone—Pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00181	0.00242	CcSEcCtD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—MAS1—primary biliary cirrhosis	0.00181	0.0073	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCR5—primary biliary cirrhosis	0.00175	0.00709	CbGpPWpGaD
Naltrexone—Feeling abnormal—Chenodeoxycholic acid—primary biliary cirrhosis	0.00175	0.00233	CcSEcCtD
Naltrexone—Feeling abnormal—Ursodeoxycholic acid—primary biliary cirrhosis	0.00175	0.00233	CcSEcCtD
Naltrexone—Hypersensitivity—Colchicine—primary biliary cirrhosis	0.00174	0.00232	CcSEcCtD
Naltrexone—Gastrointestinal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00173	0.00231	CcSEcCtD
Naltrexone—Gastrointestinal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00173	0.00231	CcSEcCtD
Naltrexone—Asthenia—Colchicine—primary biliary cirrhosis	0.00169	0.00226	CcSEcCtD
Naltrexone—Urticaria—Chenodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00225	CcSEcCtD
Naltrexone—Urticaria—Ursodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00225	CcSEcCtD
Naltrexone—Abdominal pain—Chenodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00224	CcSEcCtD
Naltrexone—Body temperature increased—Ursodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00224	CcSEcCtD
Naltrexone—Abdominal pain—Ursodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00224	CcSEcCtD
Naltrexone—Body temperature increased—Chenodeoxycholic acid—primary biliary cirrhosis	0.00168	0.00224	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL9—primary biliary cirrhosis	0.00165	0.00669	CbGpPWpGaD
Naltrexone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR5—primary biliary cirrhosis	0.00163	0.00658	CbGpPWpGaD
Naltrexone—Diarrhoea—Colchicine—primary biliary cirrhosis	0.00161	0.00216	CcSEcCtD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL9—primary biliary cirrhosis	0.00159	0.00643	CbGpPWpGaD
Naltrexone—Hypersensitivity—Chenodeoxycholic acid—primary biliary cirrhosis	0.00156	0.00209	CcSEcCtD
Naltrexone—Hypersensitivity—Ursodeoxycholic acid—primary biliary cirrhosis	0.00156	0.00209	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCR5—primary biliary cirrhosis	0.00154	0.00622	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCR5—primary biliary cirrhosis	0.00154	0.00621	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—ABCC2—primary biliary cirrhosis	0.00153	0.00619	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—CD40LG—primary biliary cirrhosis	0.00153	0.00618	CbGpPWpGaD
Naltrexone—Asthenia—Chenodeoxycholic acid—primary biliary cirrhosis	0.00152	0.00203	CcSEcCtD
Naltrexone—Asthenia—Ursodeoxycholic acid—primary biliary cirrhosis	0.00152	0.00203	CcSEcCtD
Naltrexone—Vomiting—Colchicine—primary biliary cirrhosis	0.0015	0.002	CcSEcCtD
Naltrexone—Pruritus—Ursodeoxycholic acid—primary biliary cirrhosis	0.0015	0.002	CcSEcCtD
Naltrexone—Pruritus—Chenodeoxycholic acid—primary biliary cirrhosis	0.0015	0.002	CcSEcCtD
Naltrexone—Rash—Colchicine—primary biliary cirrhosis	0.00149	0.00199	CcSEcCtD
Naltrexone—OPRM1—IL4-mediated signaling events—RPS6KB1—primary biliary cirrhosis	0.00149	0.00602	CbGpPWpGaD
Naltrexone—OPRM1—IL4-mediated signaling events—IL4—primary biliary cirrhosis	0.00149	0.00602	CbGpPWpGaD
Naltrexone—Dermatitis—Colchicine—primary biliary cirrhosis	0.00149	0.00198	CcSEcCtD
Naltrexone—Headache—Colchicine—primary biliary cirrhosis	0.00148	0.00197	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—CXCR5—primary biliary cirrhosis	0.00146	0.00589	CbGpPWpGaD
Naltrexone—Diarrhoea—Chenodeoxycholic acid—primary biliary cirrhosis	0.00145	0.00194	CcSEcCtD
Naltrexone—Diarrhoea—Ursodeoxycholic acid—primary biliary cirrhosis	0.00145	0.00194	CcSEcCtD
Naltrexone—UGT1A1—Phase II conjugation—GGT1—primary biliary cirrhosis	0.00143	0.00579	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABCG2—primary biliary cirrhosis	0.00143	0.00578	CbGpPWpGaD
Naltrexone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR5—primary biliary cirrhosis	0.00143	0.00577	CbGpPWpGaD
Naltrexone—Dizziness—Ursodeoxycholic acid—primary biliary cirrhosis	0.0014	0.00187	CcSEcCtD
Naltrexone—Dizziness—Chenodeoxycholic acid—primary biliary cirrhosis	0.0014	0.00187	CcSEcCtD
Naltrexone—Nausea—Colchicine—primary biliary cirrhosis	0.0014	0.00187	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL9—primary biliary cirrhosis	0.0014	0.00565	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL9—primary biliary cirrhosis	0.0014	0.00564	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR5—primary biliary cirrhosis	0.00139	0.00563	CbGpPWpGaD
Naltrexone—Vomiting—Chenodeoxycholic acid—primary biliary cirrhosis	0.00135	0.0018	CcSEcCtD
Naltrexone—Vomiting—Ursodeoxycholic acid—primary biliary cirrhosis	0.00135	0.0018	CcSEcCtD
Naltrexone—Rash—Chenodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00178	CcSEcCtD
Naltrexone—Rash—Ursodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00178	CcSEcCtD
Naltrexone—Dermatitis—Ursodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00178	CcSEcCtD
Naltrexone—Dermatitis—Chenodeoxycholic acid—primary biliary cirrhosis	0.00134	0.00178	CcSEcCtD
Naltrexone—Headache—Ursodeoxycholic acid—primary biliary cirrhosis	0.00133	0.00177	CcSEcCtD
Naltrexone—Headache—Chenodeoxycholic acid—primary biliary cirrhosis	0.00133	0.00177	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—CXCL9—primary biliary cirrhosis	0.00132	0.00535	CbGpPWpGaD
Naltrexone—ABCB1—Constitutive Androstane Receptor Pathway—PPARGC1A—primary biliary cirrhosis	0.00131	0.00531	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCR5—primary biliary cirrhosis	0.0013	0.00525	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL12A—primary biliary cirrhosis	0.00129	0.0052	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL9—primary biliary cirrhosis	0.00127	0.00512	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—IGFBP1—primary biliary cirrhosis	0.00126	0.00511	CbGpPWpGaD
Naltrexone—Nausea—Ursodeoxycholic acid—primary biliary cirrhosis	0.00126	0.00168	CcSEcCtD
Naltrexone—Nausea—Chenodeoxycholic acid—primary biliary cirrhosis	0.00126	0.00168	CcSEcCtD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR5—primary biliary cirrhosis	0.00122	0.00494	CbGpPWpGaD
Naltrexone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR5—primary biliary cirrhosis	0.00121	0.00487	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL9—primary biliary cirrhosis	0.00118	0.00477	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—ABCG2—primary biliary cirrhosis	0.00113	0.00455	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL9—primary biliary cirrhosis	0.00111	0.00449	CbGpPWpGaD
Naltrexone—Naloxone—ALB—primary biliary cirrhosis	0.00109	0.302	CrCbGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCR5—primary biliary cirrhosis	0.00106	0.00429	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR5—primary biliary cirrhosis	0.00103	0.00417	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL10—primary biliary cirrhosis	0.000982	0.00397	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL9—primary biliary cirrhosis	0.000963	0.0039	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GGT1—primary biliary cirrhosis	0.000955	0.00386	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL9—primary biliary cirrhosis	0.000938	0.00379	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCR5—primary biliary cirrhosis	0.00093	0.00376	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL10—primary biliary cirrhosis	0.000861	0.00348	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CCL5—primary biliary cirrhosis	0.000846	0.00342	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL9—primary biliary cirrhosis	0.000845	0.00342	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GGT1—primary biliary cirrhosis	0.000838	0.00339	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL10—primary biliary cirrhosis	0.000829	0.00335	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—DAG1—primary biliary cirrhosis	0.000817	0.0033	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL12B—primary biliary cirrhosis	0.000808	0.00327	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCR5—primary biliary cirrhosis	0.000786	0.00318	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CTLA4—primary biliary cirrhosis	0.00076	0.00307	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CCL5—primary biliary cirrhosis	0.000742	0.003	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL10—primary biliary cirrhosis	0.000728	0.00294	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL10—primary biliary cirrhosis	0.000727	0.00294	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL9—primary biliary cirrhosis	0.000714	0.00289	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—CCL5—primary biliary cirrhosis	0.000713	0.00288	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—AGT—primary biliary cirrhosis	0.000707	0.00286	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL10—primary biliary cirrhosis	0.000659	0.00266	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CCL5—primary biliary cirrhosis	0.000627	0.00253	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CCL5—primary biliary cirrhosis	0.000626	0.00253	CbGpPWpGaD
Naltrexone—OPRK1—Peptide ligand-binding receptors—AGT—primary biliary cirrhosis	0.00062	0.00251	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL10—primary biliary cirrhosis	0.000614	0.00248	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCR5—primary biliary cirrhosis	0.0006	0.00242	CbGpPWpGaD
Naltrexone—OPRD1—G alpha (i) signalling events—AGT—primary biliary cirrhosis	0.000597	0.00241	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CD40LG—primary biliary cirrhosis	0.000591	0.00239	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL10—primary biliary cirrhosis	0.000578	0.00234	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—LBR—primary biliary cirrhosis	0.000576	0.00233	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—primary biliary cirrhosis	0.000575	0.00233	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL4—primary biliary cirrhosis	0.000575	0.00232	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—primary biliary cirrhosis	0.000567	0.00229	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC4A2—primary biliary cirrhosis	0.000565	0.00228	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—NFKB1—primary biliary cirrhosis	0.000555	0.00225	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCR5—primary biliary cirrhosis	0.000544	0.0022	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL9—primary biliary cirrhosis	0.000544	0.0022	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CCL5—primary biliary cirrhosis	0.000529	0.00214	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCR5—primary biliary cirrhosis	0.000526	0.00213	CbGpPWpGaD
Naltrexone—OPRM1—Peptide ligand-binding receptors—AGT—primary biliary cirrhosis	0.000524	0.00212	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—AGT—primary biliary cirrhosis	0.000523	0.00212	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—NOS2—primary biliary cirrhosis	0.000523	0.00212	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL10—primary biliary cirrhosis	0.000502	0.00203	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—primary biliary cirrhosis	0.000497	0.00201	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL9—primary biliary cirrhosis	0.000494	0.002	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL10—primary biliary cirrhosis	0.000488	0.00197	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCR5—primary biliary cirrhosis	0.000477	0.00193	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL9—primary biliary cirrhosis	0.000477	0.00193	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—AGT—primary biliary cirrhosis	0.000474	0.00192	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCR5—primary biliary cirrhosis	0.000444	0.0018	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—AGT—primary biliary cirrhosis	0.000442	0.00179	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL10—primary biliary cirrhosis	0.00044	0.00178	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—CD80—primary biliary cirrhosis	0.00044	0.00178	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL9—primary biliary cirrhosis	0.000434	0.00175	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CCL5—primary biliary cirrhosis	0.000432	0.00175	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—primary biliary cirrhosis	0.00042	0.0017	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—OGDH—primary biliary cirrhosis	0.000417	0.00169	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—AGT—primary biliary cirrhosis	0.000416	0.00168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCR5—primary biliary cirrhosis	0.000403	0.00163	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL9—primary biliary cirrhosis	0.000403	0.00163	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—primary biliary cirrhosis	0.000381	0.00154	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CCL5—primary biliary cirrhosis	0.000379	0.00153	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL10—primary biliary cirrhosis	0.000372	0.0015	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PDHX—primary biliary cirrhosis	0.000371	0.0015	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL9—primary biliary cirrhosis	0.000366	0.00148	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—AGT—primary biliary cirrhosis	0.000361	0.00146	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—primary biliary cirrhosis	0.000352	0.00142	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—DLAT—primary biliary cirrhosis	0.000349	0.00141	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCB4—primary biliary cirrhosis	0.000349	0.00141	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDH5—primary biliary cirrhosis	0.000334	0.00135	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCR5—primary biliary cirrhosis	0.000322	0.0013	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CCL5—primary biliary cirrhosis	0.00032	0.00129	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—AGT—primary biliary cirrhosis	0.000317	0.00128	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDH5—primary biliary cirrhosis	0.000293	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL9—primary biliary cirrhosis	0.000292	0.00118	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL10—primary biliary cirrhosis	0.000284	0.00115	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCR5—primary biliary cirrhosis	0.000282	0.00114	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ELMO1—primary biliary cirrhosis	0.00027	0.00109	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—AGT—primary biliary cirrhosis	0.000268	0.00108	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LBR—primary biliary cirrhosis	0.000264	0.00107	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL10—primary biliary cirrhosis	0.000258	0.00104	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL9—primary biliary cirrhosis	0.000256	0.00104	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL10—primary biliary cirrhosis	0.000249	0.00101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDH5—primary biliary cirrhosis	0.000248	0.001	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CCL5—primary biliary cirrhosis	0.000244	0.000987	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCR5—primary biliary cirrhosis	0.000238	0.000964	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ELMO1—primary biliary cirrhosis	0.000237	0.000958	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MMP3—primary biliary cirrhosis	0.000235	0.00095	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AQP4—primary biliary cirrhosis	0.000234	0.000948	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL10—primary biliary cirrhosis	0.000226	0.000913	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ABCC2—primary biliary cirrhosis	0.000225	0.000909	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CCL5—primary biliary cirrhosis	0.000222	0.000896	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL9—primary biliary cirrhosis	0.000216	0.000875	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CCL5—primary biliary cirrhosis	0.000214	0.000865	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL10—primary biliary cirrhosis	0.00021	0.00085	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NUP210—primary biliary cirrhosis	0.00021	0.000849	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MMP3—primary biliary cirrhosis	0.000206	0.000833	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—NUP210—primary biliary cirrhosis	0.000206	0.000831	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AGT—primary biliary cirrhosis	0.000204	0.000826	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ELMO1—primary biliary cirrhosis	0.0002	0.00081	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ABCG2—primary biliary cirrhosis	0.000195	0.000789	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CCL5—primary biliary cirrhosis	0.000194	0.000786	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—OGDH—primary biliary cirrhosis	0.000191	0.000773	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ABCG2—primary biliary cirrhosis	0.000191	0.000773	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL10—primary biliary cirrhosis	0.000191	0.000772	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AGT—primary biliary cirrhosis	0.000185	0.00075	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CCL5—primary biliary cirrhosis	0.000181	0.000731	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AGT—primary biliary cirrhosis	0.000179	0.000724	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MMP3—primary biliary cirrhosis	0.000174	0.000704	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PDHX—primary biliary cirrhosis	0.00017	0.000689	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CTGF—primary biliary cirrhosis	0.000167	0.000677	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GOT2—primary biliary cirrhosis	0.000166	0.000671	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CCL5—primary biliary cirrhosis	0.000164	0.000664	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AGT—primary biliary cirrhosis	0.000163	0.000657	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DLAT—primary biliary cirrhosis	0.00016	0.000648	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCB4—primary biliary cirrhosis	0.00016	0.000648	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL10—primary biliary cirrhosis	0.000152	0.000615	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AGT—primary biliary cirrhosis	0.000151	0.000612	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GGT1—primary biliary cirrhosis	0.000143	0.000579	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GOT1—primary biliary cirrhosis	0.000143	0.000579	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—primary biliary cirrhosis	0.000143	0.000577	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP3—primary biliary cirrhosis	0.000139	0.000561	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—TYK2—primary biliary cirrhosis	0.000139	0.000561	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AGT—primary biliary cirrhosis	0.000137	0.000556	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL10—primary biliary cirrhosis	0.000133	0.000539	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCL5—primary biliary cirrhosis	0.000131	0.000529	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARGC1A—primary biliary cirrhosis	0.000127	0.000515	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	0.000127	0.000513	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP3—primary biliary cirrhosis	0.000122	0.000492	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—TYK2—primary biliary cirrhosis	0.000122	0.000492	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCL5—primary biliary cirrhosis	0.000115	0.000464	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL10—primary biliary cirrhosis	0.000113	0.000456	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	0.000111	0.00045	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HIF1A—primary biliary cirrhosis	0.00011	0.000445	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AGT—primary biliary cirrhosis	0.00011	0.000443	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP3—primary biliary cirrhosis	0.000103	0.000416	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—TYK2—primary biliary cirrhosis	0.000103	0.000416	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AGT—primary biliary cirrhosis	9.93e-05	0.000401	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCL5—primary biliary cirrhosis	9.7e-05	0.000392	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CD80—primary biliary cirrhosis	9.7e-05	0.000392	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—primary biliary cirrhosis	9.64e-05	0.00039	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NUP210—primary biliary cirrhosis	9.63e-05	0.000389	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGT—primary biliary cirrhosis	9.61e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RPS6KB1—primary biliary cirrhosis	9.4e-05	0.00038	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ABCG2—primary biliary cirrhosis	8.95e-05	0.000362	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CD80—primary biliary cirrhosis	8.51e-05	0.000344	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TYK2—primary biliary cirrhosis	8.19e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—primary biliary cirrhosis	8.15e-05	0.000329	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGT—primary biliary cirrhosis	8.12e-05	0.000328	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CTGF—primary biliary cirrhosis	7.68e-05	0.000311	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—primary biliary cirrhosis	7.62e-05	0.000308	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT2—primary biliary cirrhosis	7.61e-05	0.000308	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—primary biliary cirrhosis	7.46e-05	0.000302	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CD80—primary biliary cirrhosis	7.19e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TYK2—primary biliary cirrhosis	7.18e-05	0.00029	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GGT1—primary biliary cirrhosis	6.57e-05	0.000266	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT1—primary biliary cirrhosis	6.57e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—primary biliary cirrhosis	6.45e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NFKB1—primary biliary cirrhosis	6.38e-05	0.000258	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TYK2—primary biliary cirrhosis	6.07e-05	0.000245	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARGC1A—primary biliary cirrhosis	5.85e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—primary biliary cirrhosis	5.66e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NFKB1—primary biliary cirrhosis	5.6e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—primary biliary cirrhosis	4.78e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NFKB1—primary biliary cirrhosis	4.73e-05	0.000191	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AGT—primary biliary cirrhosis	4.55e-05	0.000184	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—primary biliary cirrhosis	3.5e-05	0.000141	CbGpPWpGaD
